PLoS ONE (Jan 2019)

Discovery of novel West Nile Virus protease inhibitor based on isobenzonafuranone and triazolic derivatives of eugenol and indan-1,3-dione scaffolds.

  • André S de Oliveira,
  • Poliana A R Gazolla,
  • Ana Flávia C da S Oliveira,
  • Wagner L Pereira,
  • Lívia C de S Viol,
  • Angélica F da S Maia,
  • Edjon G Santos,
  • Ítalo E P da Silva,
  • Tiago A de Oliveira Mendes,
  • Adalberto M da Silva,
  • Roberto S Dias,
  • Cynthia C da Silva,
  • Marcelo D Polêto,
  • Róbson R Teixeira,
  • Sergio O de Paula

DOI
https://doi.org/10.1371/journal.pone.0223017
Journal volume & issue
Vol. 14, no. 9
p. e0223017

Abstract

Read online

The West Nile Virus (WNV) NS2B-NS3 protease is an attractive target for the development of therapeutics against this arboviral pathogen. In the present investigation, the screening of a small library of fifty-eight synthetic compounds against the NS2-NB3 protease of WNV is described. The following groups of compounds were evaluated: 3-(2-aryl-2-oxoethyl)isobenzofuran-1(3H)-ones; eugenol derivatives bearing 1,2,3-triazolic functionalities; and indan-1,3-diones with 1,2,3-triazolic functionalities. The most promising of these was a eugenol derivative, namely 4-(3-(4-allyl-2-methoxyphenoxy)-propyl)-1-(2-bromobenzyl)-1H-1,2,3-triazole (35), which inhibited the protease with IC50 of 6.86 μmol L-1. Enzyme kinetic assays showed that this derivative of eugenol presents competitive inhibition behaviour. Molecular docking calculations predicted a recognition pattern involving the residues His51 and Ser135, which are members of the catalytic triad of the WNV NS2B-NS3 protease.